Zacks Investment Research cut shares of Homology Medicines (NASDAQ:FIXX) from a buy rating to a hold rating in a report published on Monday.
According to Zacks, “Homology Medicines Inc. is a genetic medicines company. Its platform offers human hematopoietic stem cell derived adeno-associated virus vectors to treat disease-causing mutations through gene correction, insertion and knockout. Homology Medicines Inc. is based in BEDFORD MA. “
Separately, B. Riley began coverage on shares of Homology Medicines in a research report on Friday, September 7th. They issued a neutral rating and a $18.50 target price for the company. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has an average rating of Buy and a consensus target price of $25.90.
Homology Medicines (NASDAQ:FIXX) last released its earnings results on Monday, August 13th. The company reported ($0.35) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.33) by ($0.02). The firm had revenue of $0.93 million for the quarter. As a group, research analysts expect that Homology Medicines will post -1.26 EPS for the current fiscal year.
Several large investors have recently made changes to their positions in FIXX. Citadel Advisors LLC bought a new stake in shares of Homology Medicines during the 1st quarter valued at about $471,000. Lord Abbett & CO. LLC bought a new stake in shares of Homology Medicines during the 1st quarter valued at about $3,740,000. Millennium Management LLC bought a new stake in shares of Homology Medicines during the 1st quarter valued at about $1,700,000. Bank of New York Mellon Corp bought a new stake in shares of Homology Medicines during the 2nd quarter valued at about $558,000. Finally, Schwab Charles Investment Management Inc. bought a new stake in shares of Homology Medicines during the 2nd quarter valued at about $998,000. 55.01% of the stock is owned by institutional investors and hedge funds.
About Homology Medicines
Homology Medicines, Inc, a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.
Featured Story: What is dollar cost averaging (DCA)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.